EZH2 and cancer: Additionally RPPA data from the TCGA [14] showed that melanoma patients with activated EZH2 (somatic mutation, copy number gains or mRNA activation) show significantly decreased levels of NDRG1_pT346, supporting the hypothesis that aberrant EZH2 activity represses tumor suppressor genes in cancer (Supplementary Figure S4B).